Results 251 to 260 of about 836,621 (308)

CCNE1: A Cell Cycle Regulator That Influences Tumor Progression

Cancer Medicine, Volume 15, Issue 10, October 2026.
ABSTRACTCyclin E1 (CCNE1), a pivotal member of the cyclin family, governs the G1/S phase transition of the cell cycle by binding to and activating cyclin‐dependent kinase 2 (CDK2), thereby initiating DNA replication and driving S‐phase entry. In a broad spectrum of human malignancies—including breast, ovarian, gastric, and non‐small cell lung cancers ...
Liang Yan, Siyi Liu, Yanling Li, Qian He, Chen Long, Ning Tang, Yanhong Zhou   +6 more
wiley   +1 more source

FTO-mediated m6A modification regulates the osteogenic differentiation of ADSCs by targeting FOXO1. [PDF]

Stem Cell Res Ther
Wang Z, Wen S, Li H, Wang X, Guo S, Yang S.   +5 more
europepmc   +1 more source

Overview on Epstein–Barr Virus–Host Interactions With a Focus on Host Cell Transcriptome Alterations

Cell Biochemistry and Function, Volume 44, Issue 10, October 2026.
ABSTRACT The Epstein–Barr virus (EBV) belongs to the gamma subgroup of human herpesviruses. EBV is particularly lymphotropic regarding its latency, meaning that it preferentially targets lymphocytes as its immunological niche. During the establishment of the complex virus–host relationships, the virus influences the human host cell transcriptome ...
Louise Wallot, Tim Hohmann, Urszula Hohmann, Faramarz Dehghani, Olaf Grisk, Simon Jasinski‐Bergner   +5 more
wiley   +1 more source

Deployment of non-canonical splicing in tunicate genomes is mediated by divergent U2AF function and changing m6A modification in U1 and U6 snRNA. [PDF]

Nucleic Acids Res
Soo TCC, Leon A, Waymel E, Barais A, Porta B, Chourrout D, Henriet S.   +6 more
europepmc   +1 more source

METTL3 Increases Temozolomide Resistance in MGMT‐Negative Glioblastoma by Enhancing CBX5 mRNA Stability in an m6A‐IGF2BP2‐Dependent Manner

CNS Neuroscience &Therapeutics, Volume 32, Issue 10, October 2026.
METTL3‐dependent m6A modification and IGF2BP2‐associated CBX5 mRNA stabilization help maintain CBX5 expression in MGMT‐negative glioblastoma. During temozolomide (TMZ) treatment, CBX5 contributes to ATM–RAD51‐associated signaling, limits persistent DNA damage and apoptosis, and thereby supports cell survival and TMZ resistance.
Hui Deng, Ruoyu Chen, Daohong Qu, Cifu Qu, Jia Shi   +4 more
wiley   +1 more source

The crosstalk of m6A modification and non-coding RNAs in gastric cancer: biomarkers and therapeutic potentials. [PDF]

Cancer Cell Int
Li P, Xue Y, Gu X.
europepmc   +1 more source

Cathepsin L in cancer: Context‐dependent functions, microenvironmental regulation and translational opportunities

Clinical and Translational Discovery, Volume 6, Issue 5, October 2026.
Cathepsin L (CTSL) acts as a context‐dependent facilitator of tumour progression rather than a universal oncogenic driver. CTSL's pro‐tumorigenic functions are critically evaluated alongside its inherent biochemical constraints and family‐wide redundancy. CTSL‐related biology may provide translational opportunities in selected contexts.
Yujun Wu, Qin Huang, Zixuan Ding, Lin Fu, Mu Yang, Bi Peng, Pengbo Hu, Yuanhui Liu   +7 more
wiley   +1 more source

Overaccumulation of miR-483-3p exerts acute toxic effects on ovarian granulosa cells by impairing cell proliferation, mitochondrial function, and METTL3-mediated m6A modification. [PDF]

PeerJ
Shen K, Dai X, Chen L, Liang Y, Huang P, Zeng Y, Qu X.   +6 more
europepmc   +1 more source

Lipid deposition promotes YTHDF3-mediated m6A modification of PPARα to facilitate liver metastasis of colorectal cancer. [PDF]

Protein Cell
Ni W, Xu Y, Zhang M, Li Y, Huang P, Li Z, Wu Q, Mo H, Ye Y, Li Y, Zhou A, Yao S, Zhi S, Qi J, Yu S, He S, Li J.   +16 more
europepmc   +1 more source